more info

Start date: 1 December 2018

End date: 29 February 2028

Number of projects: 2

Total budget: 26 592 823,86 €

EU contribution: 8 787 625,35 €

Website: n/a

Country:

European Commission Flag

Explore more: n/a

funds

ERDF: 8 787 625,35 €

Ryvu Therapeutics Spółka Akcyjna

PROGRAMMING PERIOD

1 - 2 of 2

PROJECT

TOTAL BUDGET

EU CONTRIBUTION

FUND

ONCO Prime: new possibilities for personalised cancer therapy based on primary cell culture from the patient, omic characterisation and functional tests.

10 304 277,00 €

6 321 435,69 €

ERDF

New targeted therapy for cancers with MTAP gene deletion – Phase II.

16 288 546,86 €

2 466 189,66 €

ERDF